Can-Fite BioPharma (CANF) Return on Sales (2015 - 2023)
Can-Fite BioPharma's (CANF) quarterly Return on Sales came in at 1.84% in Q4 2023, up 29.0% YoY from 1.43% in Q4 2022, and down 1832.1% on a QoQ basis from 0.1% in Q3 2023.
Can-Fite BioPharma (CANF) Return on Sales (2015 - 2023) Analysis & Trends
Can-Fite BioPharma (CANF) has 9 years of Return on Sales data on file, last reported at 1.84% in Q4 2023.
- Quarterly Return on Sales rose 29.0% year-over-year to 1.84% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 0.48% (down 2.0% YoY) and the FY2025 annual result came in at 0.24%, down 13.0% from the prior year.
- Return on Sales eased to 1.84% in Q4 2023, from 0.1% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.05% in Q1 2019 to a low of 2.13% in Q4 2022.
- A 5-year average of 0.32% and a median of 0.14% in 2021 frame the typical range for Return on Sales.
- Annual changes were most pronounced in 2022 — Return on Sales plunged 180 bps — and 2023, when it gained 29 bps.
- Tracing CANF's Return on Sales over 5 years: stood at 0.11% in 2019, then plunged by 165 bps to 0.29% in 2020, then slipped by 13 bps to 0.33% in 2021, then plunged by 548 bps to 2.13% in 2022, then advanced by 14 bps to 1.84% in 2023.
- The last three Return on Sales figures came in at 1.84% (Q4 2023), 0.1% (Q3 2023), and 0.14% (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1.84% |
| Sep 30, 2023 | -0.10% |
| Jun 30, 2023 | -0.14% |
| Mar 31, 2023 | -0.14% |
| Dec 31, 2022 | -2.13% |
| Sep 30, 2022 | -0.13% |
| Jun 30, 2022 | -0.10% |
| Mar 31, 2022 | -0.12% |
| Dec 31, 2021 | -0.33% |
| Sep 30, 2021 | -0.14% |
| Jun 30, 2021 | -0.13% |
| Mar 31, 2021 | -0.15% |
| Dec 31, 2020 | -0.29% |
| Sep 30, 2020 | -0.12% |
| Jun 30, 2020 | -0.19% |
| Mar 31, 2020 | -0.22% |
| Dec 31, 2019 | -0.11% |
| Sep 30, 2019 | -0.02% |
| Jun 30, 2019 | -0.16% |
| Mar 31, 2019 | 0.05% |